Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTONASDAQ:OTICNASDAQ:PTIXNASDAQ:SILO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTOEntero Therapeutics$0.40-1.2%$0.43$0.19▼$1.27$1.90M0.84727,545 shs65,825 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/APTIXAtrinsic$3.35-3.2%$3.83$2.35▼$15.54$1.98M0.34572,184 shs63,527 shsSILOSilo Pharma$0.61-1.2%$0.63$0.41▼$4.50$2.72M0.292.37 million shs223,006 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTOEntero Therapeutics0.00%+6.60%-22.31%-17.55%-62.24%OTICOtonomy0.00%0.00%0.00%0.00%0.00%PTIXAtrinsic0.00%-8.24%-6.22%-23.81%-71.57%SILOSilo Pharma0.00%-4.99%+4.80%-40.29%-36.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTOEntero TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/APTIXAtrinsic0.5544 of 5 stars0.05.00.00.00.01.70.0SILOSilo Pharma0.3159 of 5 stars0.02.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTOEntero Therapeutics 0.00N/AN/AN/AOTICOtonomy 0.00N/AN/AN/APTIXAtrinsic 0.00N/AN/AN/ASILOSilo Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTOEntero TherapeuticsN/AN/AN/AN/A($0.82) per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01PTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ASILOSilo Pharma$70K38.91N/AN/A$1.12 per share0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTOEntero Therapeutics-$18.06MN/A0.00∞N/AN/A-1,063.82%-26.06%N/AOTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/APTIXAtrinsic-$5.53M-$13.11N/A∞N/AN/A-860.52%-354.19%8/12/2025 (Estimated)SILOSilo Pharma-$4.39M-$1.17N/A∞N/A-6,420.83%-84.88%-61.81%8/12/2025 (Estimated)Latest OTIC, PTIX, ENTO, and SILO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ENTOEntero TherapeuticsN/A-$0.21N/A-$0.28N/AN/A5/13/2025Q1 2025PTIXAtrinsicN/A-$2.75N/A-$2.75N/AN/A5/9/2025Q1 2025SILOSilo PharmaN/A-$0.23N/A-$0.23N/A$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTOEntero TherapeuticsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ASILOSilo PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTOEntero TherapeuticsN/A2.902.90OTICOtonomyN/A1.741.74PTIXAtrinsicN/A0.860.86SILOSilo PharmaN/A4.734.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTOEntero Therapeutics12.30%OTICOtonomy41.23%PTIXAtrinsic7.97%SILOSilo Pharma5.58%Insider OwnershipCompanyInsider OwnershipENTOEntero Therapeutics0.75%OTICOtonomy1.09%PTIXAtrinsic35.00%SILOSilo Pharma4.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTOEntero Therapeutics94.77 million4.73 millionN/AOTICOtonomy5168.53 million67.78 millionOptionablePTIXAtrinsic2590,000383,000Not OptionableSILOSilo Pharma24.48 million4.29 millionNot OptionableOTIC, PTIX, ENTO, and SILO HeadlinesRecent News About These CompaniesSilo Pharma, Inc. Plans IND Application Submission for PTSD Drug SPC-15 with Potential Phase 1 Trial in 2026July 7 at 9:13 AM | quiverquant.comQSilo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025July 7 at 8:15 AM | globenewswire.comSilo Pharma Faces Nasdaq Non-Compliance NoticeJuly 3, 2025 | msn.comSilo Pharma and Hoth Therapeutics plan joint venture for obesity treatmentJune 26, 2025 | investing.comSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market - MorningstarJune 26, 2025 | morningstar.comMSilo Pharma and Hoth Therapeutics to Form Joint Venture for VA-Developed Obesity Treatment - NasdaqJune 26, 2025 | nasdaq.comSilo Pharma Enters LOI for Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketJune 26, 2025 | jcnnewswire.comJSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketJune 25, 2025 | globenewswire.comHoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.June 25, 2025 | prnewswire.comSilo Pharma, Inc.: Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsJune 11, 2025 | finanznachrichten.deSilo Pharma, Inc. Receives Notice of Allowance for Patent Strengthening SPC-15 Treatment for PTSDJune 11, 2025 | quiverquant.comQSilo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsJune 11, 2025 | globenewswire.com16 Companies Announced A Bitcoin Treasury Last Week: ReportJune 9, 2025 | coingape.comCSilo Pharma, Inc. Approves $1 Million Bitcoin Purchase as Treasury Reserve AssetJune 7, 2025 | nasdaq.comSilo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve AssetJune 5, 2025 | globenewswire.comSilo Wellness to Relist as Born Defense, a National Security Investment Issuer Focused on Ending Forever Wars and Upholding the Just War DoctrineJune 2, 2025 | newsfilecorp.comNSilo Pharma, Inc.: Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 23, 2025 | finanznachrichten.deSilo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drugMay 21, 2025 | msn.comSilo Pharma, Inc. Partners with Resyca BV for SPC-15 Drug-Device Study Aimed at PTSD TreatmentMay 21, 2025 | quiverquant.comQSilo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendAnalyst Sees Meta Hitting $800: What May Lead Shares to New HighsBy Leo Miller | June 24, 2025View Analyst Sees Meta Hitting $800: What May Lead Shares to New HighsOTIC, PTIX, ENTO, and SILO Company DescriptionsEntero Therapeutics NASDAQ:ENTO$0.40 -0.01 (-1.24%) As of 03:34 PM EasternEntero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Atrinsic NASDAQ:PTIX$3.35 -0.11 (-3.18%) As of 03:38 PM EasternProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Silo Pharma NASDAQ:SILO$0.61 -0.01 (-1.23%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Why Freeport-McMoRan Is The Copper King in a Tight Market Correction Equals Opportunity in Domino’s Pizza Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.